Gland Pharma growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+14.5%+21.1%
EBITDA+28.4%+16.7%
Net Income+47.1%+9.6%
EPS (adj.)+47.1%+9.6%
Total Assets+11.5%+12.5%
Total Equity+13.2%+9.2%
Free Cash Flow+3.2%+56.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLAND₹2,815.00

Gland Pharma Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABAUROPHARMAPPLPHARMASYNGENEWOCKPHARMAASTERDMCOHANCELALPATHLABMcap ₹46,380 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+14.5+21.1
EBITDA+28.4+16.7
Net Income+47.1+9.6
EPS (adj.)+47.1+9.6
Total Assets+11.5+12.5
Total Equity+13.2+9.2
Free Cash Flow+3.2+56.2
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.